BirdFluNews.com
RELATED LINKS
Home
 
Google

Your used Christmas tree might save you from a bird flu pandemic.

As governments worldwide scramble to stockpile the antiviral Tamiflu, generic drug maker Biolyse Pharma Corp. plans to start next month making shikimic acid, the main ingredient in the manufacture of oseltamivir, commonly known as Tamiflu, from the needles of discarded Christmas trees.

Tamiflu, as almost everybody knows by now, treats seasonal influenza and is being championed as a first line of defense against a possible pandemic outbreak of bird flu, which has been devastating chicken populations in Southeast Asia and parts of Europe.

So far, the H5N1 virus, which usually strikes people in close contact with diseased fowl or their droppings, has infected an estimated 130 people, killing 70.

INGREDIENT'S PRICE SOARS

The worry is that H5N1 will undergo a genetic mutation with a human seasonal influenza virus, morphing into a deadly strain that could spread among people like the common cold.

After being rejected as a Tamiflu supplier by Swiss drug maker F. Hoffmann-La Roche Ltd., which has a monopoly on the manufacture of the drug, Biolyse turned its sights to making shikimic acid.

Because of shortages of Tamiflu and skyrocketing demand the price of shikimic acid has soared to more than $500 a kilogram from $45 in the past 12 months.

Biolyse specializes in extracting chemicals from plants and biomaterials at its plant in St. Catharines, Ontario, and now makes a generic version of the cancer drug paclitaxel from yew trees.

"Our research has shown that 2 to 3 percent of the biomass from various pine, spruce and fir trees is extractible shikimic acid," Biolyse principal Claude Mercure said.

As the process moves from the lab to the commercial stage, he said the company aims to produce one to three tons of shikimic acid a month.

To get started, next month it will receive about 500,000 Christmas trees to be donated by Toronto-based Gro-Bark, a forestry recycling company.

Most shikimic acid is extracted from star anise, the fruit of a slow-growing evergreen in China, which is harvested for several months each year.

SPEEDING PRODUCTION

That's why Roche's production of Tamiflu takes about 12 months and there isn't nearly enough of the drug to go around for government stockpiling.

"What makes our process more viable is the fact that the particular species of pine, spruce and fir that we are working with are far more abundant than the seedlings of star anise," said John Fulton, Biolyse's vice president for new product development.

Mercure said Biolyse has no plans to make Tamiflu unless Ottawa grants compulsory licenses under the Patent Act in a national emergency.

In such a case, he said the company could produce the drug in five weeks.

In countries where Roche's patents on Tamiflu aren't recognized, such as the Philippines and Thailand, he said Biolyse is in discussions to sell shikimic acid and provide technical assistance so the drug can be manufactured for use there.

Copyright CHICAGO SUN-TIMES 2005
Provided by ProQuest Information and Learning Company. All rights Reserved.


 
Copyright ©  All Rights Reserved.
 
Related sites: